Catalog Home Page

Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics

Le, B.T., Raguraman, P., Kosbar, T.R., Fletcher, S., Wilton, S.D. and Veedu, R.N. (2018) Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Molecular Therapy - Nucleic Acids, 14 (1). pp. 142-157.

[img]
Preview
PDF - Published Version
Download (1MB) | Preview
Free to read: https://doi.org/10.1016/j.omtn.2018.11.007
*No subscription required

Abstract

Cancer is one of the leading causes of death worldwide and conventional cancer therapies such as surgery, chemotherapy and radiotherapy do not address the underlying molecular pathologies, leading to inadequate treatment and tumour recurrence. Angiogenic factors, such as EGF, PDGF, bFGF, TGF-β, TGF-α, VEGF, Endoglin and Angiopoietins play important roles in regulating tumour development and metastasis, and serve as potential targets for developing cancer therapeutics. Nucleic acid-based therapeutic strategies have received significant attention in the last two decades, and antisense oligonucleotide-mediated intervention is a prominent therapeutic approach for targeted manipulation of gene expression. Clinical benefits of antisense oligonucleotides have been recognised by the US Food and Drug Administration, with full or conditional approval of Vitravene, Kynamro, Exondys51 and Spinraza. Herein, we review the scope of antisense oligonucleotides that target angiogenic factors towards tackling solid cancers.

Publication Type: Journal Article
Murdoch Affiliation: Centre for Comparative Genomics
Publisher: Cell Press
Copyright: © 2018 The Author(s)
URI: http://researchrepository.murdoch.edu.au/id/eprint/42680
Item Control Page Item Control Page

Downloads

Downloads per month over past year